Pilot Study of Enalapril and Renal Function in Patients With IgA Nephropathy
OBJECTIVES: I. Determine the most sensitive outcome measures (functional or morphological) of a progressive renal injury in patients with IgA nephropathy.
II. Determine which of these patients are destined to progress to further injury in order to target them for therapy.
III. Elucidate the determinants of progression in those patients who exhibit evidence of either increasing impairment of ultrafiltration capacity or ongoing destruction of nephrons.
|Study Design:||Primary Purpose: Treatment|
|Study Start Date:||May 2000|
PROTOCOL OUTLINE: Patients receive oral enalapril daily. Treatment continues for 5 years in the absence of unacceptable toxicity.
Patients undergo renal function studies every 6-12 months for 5 years. Patients undergo renal biopsy at 36-48 months after study entry.
|Study Chair:||Bryan D. Myers||Stanford University|